BMEA250117P500
- 0.00
- 0.000.00%
Biomea Fusion Newsroom
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $30
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial Outlook
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
Biomea Fusion Is Maintained at Buy by D. Boral Capital
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Analyst Ratings
Biomea Fusion's Innovative Diabetes Therapy Boosts Buy Rating With Promising Preclinical Data on Icovamenib
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
Scotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
Biomea Fusion Is Maintained at Buy by D. Boral Capital
J.P. Morgan Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11
Biomea Fusion Analyst Ratings
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Promising Phase 1 Results for Biomea Fusion's BMF-500 Support Buy Rating